The company remains pre-revenue, with operating losses widening to $159.6 million in 2026Q4 as R&D spending surged to $142.3 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 409K | 0 | 0 | 0 | 0 | 0 | 21K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -409K | 0 | 0 | 0 | 0 | 0 | -21K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | 100% | - | - | - |
| Operating Expenses | 532.9M | 438.15M | 270.21M | 208.28M | 156.03M | 108.12M | 59.66M | 448 | 136.74M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 76.24M | 77.23M | 57.28M | 48.02M | 54.23M | 39.51M | 11.73M | 448 | 1.48M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 456.66M | 360.92M | 212.93M | 160.26M | 101.81M | 68.6M | 47.93M | 25.73M | 135.26M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -532.9M | -438.15M | -270.21M | -208.28M | -156.03M | -108.12M | -59.68M | -450 | -136.74M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -21.62% | -62.15% | -29.74% | -33.48% | -44.32% | -81.17% | -13261677.78% | 100% | - |
| EBITDA | -532.49M | -437.77M | -269.98M | -208.08M | -155.91M | -108.05M | -59.66M | 9.55K | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -21.64% | -62.15% | -29.75% | -33.47% | -44.29% | -81.12% | -624780.63% | - | - |
| D&A (Non-Cash Add-back) | 409K | 377K | 231K | 193K | 126K | 65K | 21K | 10K | 136.74M |
| EBIT | -532.9M | -438.15M | -270.21M | -208.28M | -156.03M | -108.12M | -65.67M | -448 | -136.74M |
| Net Interest Income | 25.33M | 24.73M | 24.95M | -4.9M | 0 | 0 | -624.38K | 0 | 0 |
| Interest Income | 25.33M | 24.73M | 24.95M | 7.58M | - | 0 | 625 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 12.48M | - | 0 | 625K | 0 | 0 |
| Other Income/Expense | 27.51M | 25.2M | 11.44M | -2.67M | -781K | 328K | -6.61M | 0 | 116 |
| Pretax Income | -505.39M | -412.95M | -258.77M | -210.95M | -156.81M | -107.79M | -66.29M | -448 | -136.74M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 215K | 891K | 567K | 9K | -84K | -358K | 97K | 0 | 0 |
| Effective Tax Rate % | -0.04% | -0.22% | -0.22% | -0% | 0.05% | 0.33% | -0.15% | 0% | 0% |
| Net Income | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -448 | -136.74M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -22.17% | -59.58% | -22.93% | -34.6% | -45.89% | -61.82% | -14818650% | 100% | - |
| Net Income (Continuing) | -505.61M | -413.84M | -259.34M | -210.96M | -156.73M | -107.43M | -66.39M | -448 | -136.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.67 |
| EPS Growth % | -1.47% | -45.21% | -9.94% | -19.58% | -17.21% | 20.78% | - | 100% | - |
| EPS (Basic) | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | 0.00 | -13.68 |
| Diluted Shares Outstanding | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 14.38M | 10M |
| Basic Shares Outstanding | 182.42M | 151.57M | 138.1M | 123.08M | 109.68M | 87.76M | 43.2M | 14.38M | 10M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As indicated by recent financial disclosures, Immunovant's quarterly R&D expenditures have surged to $142.3 million in 2026Q4, reflecting an aggressive push to advance its clinical pipeline while maintaining a pre-revenue status that necessitates continuous reliance on external capital markets to fund ongoing operational requirements.
The consistent upward trajectory in R&D spending suggests that the company is prioritizing the acceleration of its Phase 3 programs over near-term expense discipline. Investors should monitor whether this elevated spending level is a temporary peak associated with trial enrollment or a structural shift in the company's long-term cost base.
Based on the company's reported income statements, the absence of commercial revenue coupled with rising operating expenses has resulted in a widening operating loss, which reached $159.6 million in 2026Q4, highlighting the significant financial burden of maintaining a late-stage biotechnology development platform without any offsetting product sales.
The lack of operating leverage is expected for a clinical-stage entity, yet the scale of the loss underscores the high-stakes nature of the current development cycle. The company's ability to manage these losses depends entirely on the successful clinical validation of its lead assets rather than operational efficiency.
According to quarterly filings, Immunovant consistently records stock-based compensation expenses, with $11.1 million reported in 2026Q4, which serves as a non-cash component of the operating loss and contributes to the ongoing dilution of existing shareholders as the company funds its operations through equity-linked incentives.
While stock-based compensation is a standard tool for talent retention in the biotech sector, its persistence in a pre-revenue environment warrants careful scrutiny regarding the total cost of capital. Investors should consider the impact of these recurring non-cash charges on the company's long-term equity value and potential for future dilution.
As reported in financial statements, the company faces a challenging path to profitability, with the potential for future margin compression if the entry of well-capitalized competitors into the FcRn space forces a shift toward a more commoditized pricing environment for its lead therapeutic candidates.
The market's current valuation appears to assume a best-in-class profile for IMVT-1402, yet the emergence of large-cap rivals suggests that commercialization costs may be higher than initially anticipated. This competitive landscape may necessitate significant strategic pivots that could further strain the company's financial position.
Quick answers to the most common questions about buying IMVT stock.
For fiscal year 2026, Immunovant, Inc. (IMVT) reported total revenue of $0.0M.
Immunovant, Inc. (IMVT) reported a net loss of $505.6M for the fiscal year ending 2026.